CSIMarket Company Name, Ticker, Suppliers, else..
 
Seres Therapeutics Inc   (NASDAQ: MCRB)
 
Price: $5.0600 $-0.04 -0.784%
Day's High: $5.239999771118164 Week Perf: -11.54 %
Day's Low: $ 5.00 30 Day Perf: 7.2 %
Volume (M): 24,441 52 Wk High: $ 29.98
Volume (M$): $ 0 52 Wk Avg: $11.16
Open: $5.17 52 Wk Low: $4.32



 Market Capitalization (Millions $) 49
 Shares Outstanding (Millions) 10
 Employees 66
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 0

Business Description


Seres Therapeutics Inc is a biotechnology company that specializes in the development of microbiome therapeutics. The company focuses on researching and utilizing the microorganisms that reside in the human gut to develop innovative therapies for various diseases. Seres Therapeutics aims to treat serious diseases by targeting the microbiome, which plays a crucial role in our immune system, metabolism, and overall health. The company's goal is to harness the power of the microbiome to improve the lives of patients suffering from conditions such as inflammatory bowel disease, infectious diseases, and metabolic disorders. Seres Therapeutics is headquartered in Cambridge, Massachusetts and was founded in 2010.


   Company Address: 101 Cambridgepark Drive Cambridge 2140 MA
   Company Phone Number: 945-9626   Stock Exchange / Ticker: NASDAQ MCRB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
APRE   -3.29%    
• View Complete Report
   



Clinical Study

Seres Therapeutics Secures $3.6 Million CARB-X Award for SER-155 Liquid Formulation to Combat AMR Infections

Published Wed, Oct 29 2025 1:35 PM UTC

: Seres Therapeutics, a pioneering company in microbiome therapeutics, has announced the receipt of a significant financial boost from CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) with an award of up to $3.6 million. The funding aims to advance the development of a liquid formulation of SER-155, designed to prevent bloodstream and antimicrob...
Clinical Study

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

Published Tue, May 27 2025 12:21 PM UTC

Exploring the Therapeutic Potential of SER-155: Insights from Biomarker Data and Economic Challenges of Seres Therapeutics The landscape of post-transplant care has continuously evolved, with recent advancements focusing on enhancing immune recovery and reducing complications after allogeneic hematopoietic stem cell transplantation (alloHSCT). Seres Therapeutics has made si...
Management Announcement

Seres Therapeutics Finalizes VOWST Sale to Nestlé Health Science Amid Financial Losses, Focuses on Advancing Live Biotherapeutics Development,

Published Mon, Sep 30 2024 9:15 PM UTC

In a landmark strategic move, Seres Therapeutics, Inc. (Nasdaq: MCRB), headquartered in Cambridge, Massachusetts, has successfully completed the sale of its VOWST business to Societé des Produits Nestlé S.A. a subsidiary of Nestlé Health Science. This decision comes as part of Seres’ broader strategy to align its resources on the development of its core offerings, parti...
Clinical Study

Seres Therapeutics Stockholders Approve Sale of VOWST to Nestl Health Science; Sale Expected to Close on September 30

Published Thu, Sep 26 2024 8:01 PM UTC

Seres Therapeutics Gains Stockholder Endorsement for VOWST Sale to Nestlé Health Science, Anticipated Closure by Month-EndIn a strategic move that underscores the evolving landscape of biotherapeutics, Seres Therapeutics, Inc. (Nasdaq: MCRB), headquartered in Cambridge, Massachusetts, has announced the successful approval of its shareholders for the sale of its VOWST busin...
Clinical Study

SER-155 Shows Promise in Reducing Infection Rates and Antibiotic Use Post-Allogeneic Hematopoietic Stem Cell Transpla...

Published Thu, Sep 12 2024 11:00 AM UTC

Seres Therapeutics has reported promising findings from its Phase 1b placebo-controlled trial evaluating SER-155 in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study demonstrated that SER-155 administration was significantly associated with a reduction in bacterial bloodstream infections (BSIs), systemic antibiotic exposure, and f...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 26.19
Price to Sales (Expected) -
Price to Book 1.43
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.78
Working Capital Ratio 2.11
Leverage Ratio (MRQ) 1.94
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.4 $
Revenues (TTM) 0.19 $
Cash Flow (TTM) -
Cash 1.6 $
Book Value 3.54 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 28,530
Net Income per Employee (TTM) -340,348
Receivable Turnover Ratio (TTM) 7.42
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -2890.35 %
Net Margin (MRQ) 622.42 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Seres Therapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.